Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Progressive Corp (PGR) Price & Performance

Eli Lilly And CoTrade
Progressive CorpTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Progressive Corp — how do they compare? Eli Lilly And Co trades at $1,223.38 (market cap $1.08T), while Progressive Corp trades at $209.56 (market cap $123.45B). The key difference: Eli Lilly And Co is far larger — about 8.7× Progressive Corp's market cap, and Progressive Corp pays the higher dividend (6.55%). Which is the better fit depends on your goals.

LLYPGR
Market Cap
$1.08T$123.45B
Sector
HealthFinancials
52-Week High
$1.24K$252.68
52-Week Low
$639.43$190.40
Enterprise Value
$1.13T$131.66B
Dividend Yield
0.57%6.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Progressive Corp

Progressive (PGR) trades at $213.95, down 0.64% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamental performance with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Recent Q2 2026 earnings beat expectations at $4.85 per share, though the combined ratio widened to 87.1%, indicating potential growth trade-offs. Analyst consensus price target stands at $231.20 with 37% buy ratings.

PGR presents a compelling investment case with reasonable valuation (P/E 10.65) and strong profitability (ROE 34.94%), though investors face risks from competitive pressures and potential margin compression as the company expands its bundled insurance offerings. The stock offers 8% upside to consensus target with balanced risk-reward profile.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Progressive Corp

Progressive underwrites private and commercial auto insurance and specialty lines

Read more on PGR